Because it is a strong prognostic factor in both low-grade and anaplastic oligodendrogliomas, and is predictive of response to both chemo- and radiotherapy, 1p/19q codeletion is currently used as ...

The Phase III STELLAR trial evaluated the eflornithine and lomustine combination in patients with IDH mutant astrocytoma.

When my daughter was diagnosed with a rare form of brain cancer, I was unsure about clinical trials but eventually learned that it was a lifeline that would save her.